Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Enterprise Value (2024 - 2025)

Historic Enterprise Value for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$103.8 million.

  • Xilio Therapeutics' Enterprise Value fell 6938.57% to -$103.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.8 million, marking a year-over-year decrease of 6938.57%. This contributed to the annual value of -$55.3 million for FY2024, which is N/A changed from last year.
  • Per Xilio Therapeutics' latest filing, its Enterprise Value stood at -$103.8 million for Q3 2025, which was down 6938.57% from -$121.6 million recorded in Q2 2025.
  • Xilio Therapeutics' 5-year Enterprise Value high stood at -$34.0 million for Q1 2024, and its period low was -$121.6 million during Q2 2025.